# BPC-157 TB-500 Dosage in the Research Literature (Research Context) > BPC-157 TB-500 dosage as reported in the research literature: animal doses by constituent, no validated blend dose, half-life data, and routes. Research context only — not human-use guidance. What was administered to which species, by which route, at which dose. There is no validated human dose for the blend or either constituent, and none is recommended here. ## BPC-157 TB-500 dosage in the research literature There is no validated dose for the BPC-157 TB-500 blend. Commercial research-product labeling commonly pairs the two peptides at fixed combined masses per vial — for example, approximately 10 mg BPC-157 plus 10 mg TB-500, or a single 20 mg combined vial — but no peer-reviewed combination dose-finding study exists [1]. Everything below is research context: doses given to animals in published studies, described as "studied at X in [species]," never as guidance for people. The blend has no dose because the blend has no controlled study; the numbers that do exist describe one constituent at a time, in one species at a time. The figures that exist are per constituent. For the **BPC-157** leg, rodent studies commonly express dose by body weight, frequently around 10 μg/kg and 10 ng/kg in tendon-repair work [1], with gastric-ulcer cytoprotection studied at 400–800 ng/kg in rats [1]. The striking feature of the BPC-157 record is how low and how wide that range runs — from nanograms to micrograms per kilogram — which is one reason no single "dose" can be lifted from it [1]. For the **TB-500 / Thymosin Beta-4** leg, the range is wider still, and one study makes the danger of extrapolation explicit. A rat embolic-stroke dose-response study spanned 2–18 mg/kg intraperitoneally, with the modeled optimum near 3.75 mg/kg — and the top dose, 18 mg/kg, gave no benefit at all [4]. The dose-response was non-monotonic: more was not better, and the highest dose was effectively inert [4]. A separate muscular-dystrophy study used 150 μg of Thymosin Beta-4 twice weekly intraperitoneally for six months, yet chronic dosing increased regenerating fibers without improving strength, cardiac function, or fibrosis [4]. Both results undercut the "loading" logic that community blend protocols are built on. Human single-agent reference points exist only for full-length Thymosin Beta-4, not the blend or the fragment: intravenous Thymosin Beta-4 was well tolerated up to 1,260 mg in a Phase 1 study [4]. That tolerability figure is frequently cited to reassure, but it describes the parent protein given intravenously in a safety study, not the BPC-157 TB-500 pairing at any dose or route [4]. Community "loading then maintenance" blend protocols have no controlled-trial basis [6]. ## Half-life and pharmacokinetics #### What is the half-life of BPC-157 and TB-500? No validated human half-life exists for either constituent at research-use doses, and none for the blend [1]. BPC-157 elimination half-life was reported as under 30 minutes in a rat/dog pharmacokinetic study [1]. No specific half-life is established for the TB-500 heptapeptide; human intravenous Thymosin Beta-4 showed dose-proportional pharmacokinetics with half-life increasing at higher doses, but that is the full-length protein, not the fragment [4]. The practical consequence is that the blend has no pharmacokinetic profile of its own. The most-cited number — BPC-157's sub-30-minute rat half-life — describes one constituent in one species, and cannot be read across to a human-use schedule [1]. For the full-length Thymosin Beta-4 the half-life lengthened with dose in the human IV studies, which means even the parent protein has no single half-life to quote, let alone the 7-mer fragment or the pairing [4]. ## Routes studied for the Wolverine blend Across the underlying single-compound studies, several routes appear. Intraperitoneal administration predominates in the rodent efficacy studies for both peptides [1]. Intravenous dosing appears in the human Phase 1 work on full-length Thymosin Beta-4 and in a small BPC-157 IV safety pilot [4]. Local, intra-lesional, and topical routes appear in individual-compound wound and tendon models [4]. #### What is a wolverine injection in the research context? The phrase refers to subcutaneous or intramuscular administration of the BPC-157/TB-500 pairing — the predominant research-community routes for the blend, which are not drawn from controlled human efficacy trials [1]. The injectable route is also the one FDA's safety concern centers on for both constituents, as set out in the [Wolverine legal status and FDA 503A category](/legal-status). ##### Oral versus injectable: what the research says BPC-157 is studied as a "stable gastric" peptide, which is why oral BPC-157 products are marketed; the term "bpc 157 tb 500 oral" refers to this peroral form [1]. But blend oral products lack validated pharmacokinetics — no study establishes oral absorption or a half-life for the pairing — so the oral-versus-injectable question has no evidence-based answer for the blend [1]. ## Reconstitution and handling #### How do you reconstitute a BPC-157 / TB-500 blend (10mg)? Both constituents are supplied as lyophilized powders, reconstituted in bacteriostatic or sterile water and refrigerated for research handling [1]. A common practice is to reconstitute the two peptides separately or in a shared vial. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed [1]. This is research-handling context, not human-use guidance. #### How often should you inject BPC-157 and TB-500? There is no validated injection schedule for the blend. Community "loading then maintenance" protocols have no controlled-trial basis [6]. The underlying animal studies used widely varying doses and schedules per compound — from 10 ng/kg to milligram-per-kilogram ranges — and the blend has no peer-reviewed dose-finding study [4]. Two handling caveats compound each other for the blend. The first is identity: in unregulated material, the actual BPC-157:TB-500 ratio is not guaranteed, and the TB-500 component is the short Ac-LKKTETQ fragment rather than the full-length Thymosin Beta-4 that carries most of the efficacy data [5]. The second is purity: outside formal studies, product identity and purity are unverified, which is why the figures on this page describe what was administered in published research, not what is in any given vial [1]. Taken together, there is no reliable mapping from a labeled blend dose to the doses used in the cited animal studies. --- Two repair signals read at a forge's distance — BPC-157's ember leg and TB-500's amethyst leg, each weighed against its own studies, the join between them left theoretical and the FDA 503A status struck first; no clinic at the anvil and nothing here dispensed.